Histopathology and surgical outcome of symptomatic treatment-related changes after gamma knife radiosurgery in patients with brain metastases.
Jeong-Hwa KimJung-Won ChoiDoo-Sik KongHo Jun SeolDo-Hyun NamJae-Wook RyuSung Tae KimYeon-Lim SuhJung-Il LeePublished in: Scientific reports (2022)
A late-onset treatment-related changes (TRCs), which represent radiographic radiation necrosis (RN), frequently occur after stereotactic radiosurgery (SRS) for brain metastases and often need surgical treatment. This study aimed to validate the true pathology and investigate clinical implication of surgically resected TRCs on advanced magnetic resonance imaging (MRI). Retrospective analyses of 86 patients who underwent surgical resection after radiosurgery of brain metastases were performed. Fifty-four patients displayed TRCs on preoperative MRI, comprising pure RN in 19 patients (TRC-RN group) and mixed viable tumor cells in 35 patients (TRC-PD group). Thirty-two patients revealed the consistent diagnosis of progressive disease in both MRI and histopathology (PD-PD group). The TRC-PD group showed larger prescription isodose volume (9.4 cm 3 ) than the TRC-RN (4.06 cm 3 , p = 0.014) group and a shorter time interval from SRS to preoperative MRI diagnosis (median 4.07 months) than the PD-PD group (median 8.77 months, p = 0.004). Progression-free survival was significantly different among the three groups (p < 0.001), but not between TRC-RN and TRC-PD (post hoc test, p = 1.00), while no difference was observed in overall survival (p = 0.067). Brain metastases featured as TRCs after SRS frequently contained viable tumor cells. However, this histologic heterogeneity had a minor impact on benign local prognosis of TRCs after surgical resection.
Keyphrases
- brain metastases
- end stage renal disease
- magnetic resonance imaging
- small cell lung cancer
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- late onset
- peritoneal dialysis
- computed tomography
- contrast enhanced
- multiple sclerosis
- patients undergoing
- magnetic resonance
- single cell
- combination therapy